secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2024-05-09T23:59:59+00:00
Accession:  0001636282-24-000039
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre reports Q1 net loss $43.9M; cash $485M; SPY001 on track for FIH Q2 2024
-----------------------------------------------------------------------------

- Net loss of $43.9M for Q1 2024, including $13.8M non-cash stock comp; vs $18.4M loss in Q1 2023.
- Cash, equivalents, marketable securities, and restricted cash total $485M as of March 31, 2024.
- Raised $180M in March 2024 private placement; expected runway into 2027 through clinical readouts.
- SPY001 (anti-α4β7) cleared 28-day GLP tox; FIH study to start Q2 2024 with interim data expected year-end 2024.
- SPY002 (anti-TL1A) on track for FIH in H2 2024; SPY003 (anti-IL-23 p19) candidate nomination set for mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628224000039/0001636282-24-000039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628224000039/syre-20240509.htm
  HTML page:      https://secwatch.observer/filing/0001636282-24-000039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer